Biogen's new MS drug tops expectations, earnings rise

Oct 28 (Reuters) - Biogen Idec on Monday reported $286 million in third-quarter sales of its high-profile new multiple sclerosis drug Tecfidera, providing fresh evidence that the medicine is off to...

from Reuters: Mergers News http://feeds.reuters.com/~r/reuters/mergersNews/~3/_WsjdD46FxA/story01.htm